Sei Investments Co. increases stock position in LeMaitre Vascular, Inc. (NASDAQ:LMAT)

VaselineOctober 2, 2024

0 5 minutes read

Sei Investments Co. increased its position in LeMaitre Vascular, Inc. (NASDAQ:LMAT – Free Report) by 2.0% during the second quarter, HoldingsChannel.com reports. The firm owned 59,211 shares of the medical instruments supplier’s stock after acquiring an additional 1,140 shares during the period. Sei Investments Co. holdings. in LeMaitre Vascular were worth $4,872,000 as of its most recent SEC filing.

Several other hedge funds have also modified their holdings of the company. Shaker Investments LLC OH raised its position in LeMaitre Vascular by 1.3% during the second quarter. Shaker Investments LLC OH now owns 13,833 shares of the medical instruments supplier’s stock valued at $1,138,000 after acquiring an additional 175 shares in the last quarter. GAMMA Investing LLC grew its position in shares of LeMaitre Vascular by 57.0% in the second quarter. GAMMA Investing LLC now owns 548 shares of the medical instruments supplier’s stock worth $45,000 after acquiring an additional 199 shares in the last quarter. nVerses Capital LLC boosted its holdings in shares of LeMaitre Vascular by 33.3% during the 2nd quarter. nVerses Capital LLC now owns 800 shares of the medical instruments supplier’s stock worth $66,000 after buying an additional 200 shares shares in the last quarter. Albion Financial Group UT boosted its position in shares of LeMaitre Vascular by 5.6% in the first quarter. Albion Financial Group UT now owns 3,974 shares of the medical instruments supplier’s stock worth $264,000 after buying an additional 212 shares during the last quarter. Finally, Texas Permanent School Fund Corp raised its stake in LeMaitre Vascular by 1.3% in the first quarter. Texas Permanent School Fund Corp now owns 17,341 shares of the medical instruments supplier’s stock worth $1,151,000 after purchasing an additional 225 shares during the last quarter. 84.64% of the shares are held by hedge funds and other institutional investors.

LeMaitre Vascular stock down 2.2%

Shares of NASDAQ LMAT opened at $90.86 on Wednesday. LeMaitre Vascular, Inc. it has a 52-week low of $44.27 and a 52-week high of $93.24. The company’s 50-day moving average price is $87.38 and its 200-day moving average price is $79.16. The firm has a market cap of $2.04 billion, a P/E ratio of 60.17, a P/E/G ratio of 2.41 and a beta of 0.88.

Want more great investment ideas?

LeMaitre Vascular (NASDAQ:LMAT – Get Your Free Report ) last issued its quarterly earnings data on Thursday, August 1st. The medical instruments supplier reported $0.52 earnings per share for the quarter, beating analysts’ consensus estimates of $0.47 by $0.05. The firm had revenue of $55.85 million for the quarter, compared to analyst estimates of $54.98 million. LeMaitre Vascular had a net margin of 18.33% and a return on equity of 12.41%. The company’s quarterly revenue was up 11.4% compared to the same quarter last year. In the same quarter last year, the company earned $0.37 per share. As a group, research analysts expect LeMaitre Vascular, Inc. to post 1.85 earnings per share for the current year.

LeMaitre Vascular Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Thursday, August 29th. Stockholders of record on Thursday, August 15th were issued a $0.16 dividend. The ex-dividend date of this dividend was Thursday, August 15. This represents an annualized dividend of $0.64 and a dividend yield of 0.70%. LeMaitre Vascular’s dividend payout ratio (DPR) is currently 42.38%.

Changes in Analyst Ratings

A number of equities research analysts have commented on LMAT shares. Barrington Research reiterated an “outperform” rating and issued a $92.00 target price on shares of LeMaitre Vascular in a research note on Friday, September 20th. StockNews.com cut shares of LeMaitre Vascular from a “buy” rating to a “hold” rating in a research report on Tuesday, August 27th. JMP Securities upped their target price on shares of LeMaitre Vascular from $77.00 to $100.00 and gave the stock a “market outperform” rating in a research report on Tuesday, August 20th. Finally, Lake Street Capital initiated coverage on shares of LeMaitre Vascular in a report on Friday, August 2nd. They issued a “buy” rating and a $105.00 price target for the company. Two investment analysts have rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $94.40, based on data from MarketBeat.

See our latest review on LeMaitre Vascular

Insider trading at LeMaitre Vascular

In other LeMaitre Vascular news, CEO George W. Lemaitre sold 12,976 shares of the business’s stock in a transaction that occurred on Friday, July 12th. The stock was sold at an average price of $86.07, for a total value of $1,116,844.32. Following the sale, the chief executive officer now owns 1,985,358 shares in the company, valued at approximately $170,879,763.06. The transaction was disclosed in a legal filing with the SEC, which is available on the SEC’s website. In related news, Director David B. Roberts sold 3,063 shares of LeMaitre Vascular stock in a transaction dated Tuesday, August 13th. The stock was sold at an average price of $82.07, for a total value of $251,380.41. Following the completion of the transaction, the director now owns 14,114 shares in the company, valued at approximately $1,158,335.98. The sale was disclosed in a filing with the SEC, which is available on the SEC’s website. Also, CEO George W. Lemaitre sold 12,976 shares of the stock in a transaction that occurred on Friday, July 12th. The stock was sold at an average price of $86.07, for a total value of $1,116,844.32. Following the transaction, the chief executive officer now owns 1,985,358 shares in the company, valued at approximately $170,879,763.06. The disclosure for this sale can be found here. Insiders sold 43,251 shares of company stock worth $3,714,994 in the last quarter. 10.79% of shares are currently owned by insiders.

LeMaitre Vascular Company Profile

(Free Report)

LeMaitre Vascular, Inc develops, manufactures and markets medical devices and implants used in vascular surgery worldwide. Provides cryopreservation services for human cadaver tissue; angioscope, a fiber optic catheter used to view the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi from the venous system; occlusion catheters that temporarily block blood flow; and infusion catheters to infuse blood and other fluids into the vascular system.